United Therapeutics (NASDAQ:UTHR) CEO Sells $4,812,605.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $506.59, for a total transaction of $4,812,605.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $164,359,579.37. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $9.79 during midday trading on Tuesday, hitting $518.27. The company’s stock had a trading volume of 366,401 shares, compared to its average volume of 491,932. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The firm’s fifty day moving average price is $535.22 and its 200-day moving average price is $536.38. The firm has a market cap of $22.23 billion, a P/E ratio of 18.54, a P/E/G ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter last year, the company posted $6.41 earnings per share. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. As a group, research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on UTHR. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $646.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. Fiduciary Financial Advisors bought a new stake in shares of United Therapeutics during the second quarter valued at about $30,000. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Finally, Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.